LA telehealth startup’s rapid scale-up
What happened
A self-taught Los Angeles founder, Matthew Gallagher, reportedly grew Medvi — a GLP‑1 telehealth business — to $401 million in revenue in its first year using AI tools and a two-person team. The rapid scale and margin profile are being held up as an example of generalists using AI to accelerate go‑to‑market, and the company projects further growth into 2026. For LA startup hiring and product storytelling, it’s an explicit example of AI-enabled operational leverage. (x.com)
Why it matters
Medvi was launched in September 2024 after founder Matthew Gallagher put roughly $20,000 into the effort. (forbes.com) By the end of 2025 the business reported about 250,000 paying customers and had one full‑time hire, Gallagher’s brother Elliot, while most operational work ran through contractors and platform partners. (pymnts.com) The public profile of the company highlights heavy use of large language models — that is, AI systems trained on massive text collections to generate code and marketing copy — with named tools including ChatGPT, Claude and Grok, plus image/video generators like MidJourney and Runway and voice tools such as ElevenLabs. (pymnts.com) Medvi deliberately split the stack: Gallagher runs the consumer brand, website, paid ads, checkout and service, while licensed clinical work and pharmacy fulfillment are provided by third‑party telehealth platforms (a model sometimes called “telehealth‑as‑a‑service”), with partners named in reporting including CareValidate and OpenLoop Health. (arr.club) Early traction numbers published in the reporting show about 300 customers in month one and roughly 1,300 in month two, and the company’s disclosed unit economics were summarized with a reported net margin around 16.2 percent (about $65 million of profit on the reported sales figure). (arr.club) Regulatory scrutiny is already on record: the U.S. Food and Drug Administration sent MEDVi a warning letter dated February 20, 2026 that flagged the site’s marketing of “compounded” semaglutide and tirzepatide — meaning pharmacy‑made formulations that are not FDA‑approved — as false or misleading, and the agency separately issued a batch of warning letters in early March 2026 targeting telehealth marketing of compounded GLP‑1 products. (fda.gov 1) (fda.gov 2)
Key numbers
- A self-taught Los Angeles founder, Matthew Gallagher, reportedly grew Medvi — a GLP‑1 telehealth business — to $401 million in revenue in its first year using AI tools and a two-person team.
- The rapid scale and margin profile are being held up as an example of generalists using AI to accelerate go‑to‑market, and the company projects further growth into 2026.
- (x.com) Medvi was launched in September 2024 after founder Matthew Gallagher put roughly $20,000 into the effort.
- (forbes.com) By the end of 2025 the business reported about 250,000 paying customers and had one full‑time hire, Gallagher’s brother Elliot, while most operational work ran through contractors and platform partners.
Quick answers
What happened in LA telehealth startup’s rapid scale-up?
A self-taught Los Angeles founder, Matthew Gallagher, reportedly grew Medvi — a GLP‑1 telehealth business — to $401 million in revenue in its first year using AI tools and a two-person team. The rapid scale and margin profile are being held up as an example of generalists using AI to accelerate go‑to‑market, and the company projects further growth into 2026. For LA startup hiring and product storytelling, it’s an explicit example of AI-enabled operational leverage. (x.com)
Why does LA telehealth startup’s rapid scale-up matter?
Medvi was launched in September 2024 after founder Matthew Gallagher put roughly $20,000 into the effort. (forbes.com) By the end of 2025 the business reported about 250,000 paying customers and had one full‑time hire, Gallagher’s brother Elliot, while most operational work ran through contractors and platform partners. (pymnts.com) The public profile of the company highlights heavy use of large language models — that is, AI systems trained on massive text collections to generate code and marketing copy — with named tools including ChatGPT, Claude and Grok, plus image/video generators like MidJourney and Runway and voice tools such as ElevenLabs. (pymnts.com) Medvi deliberately split the stack: Gallagher runs the consumer brand, website, paid ads, checkout and service, while licensed clinical work and pharmacy fulfillment are provided by third‑party telehealth platforms (a model sometimes called “telehealth‑as‑a‑service”), with partners named in reporting including CareValidate and OpenLoop Health. (arr.club) Early traction numbers published in the reporting show about 300 customers in month one and roughly 1,300 in month two, and the company’s disclosed unit economics were summarized with a reported net margin around 16.2 percent (about $65 million of profit on the reported sales figure). (arr.club) Regulatory scrutiny is already on record: the U.S. Food and Drug Administration sent MEDVi a warning letter dated February 20, 2026 that flagged the site’s marketing of “compounded” semaglutide and tirzepatide — meaning pharmacy‑made formulations that are not FDA‑approved — as false or misleading, and the agency separately issued a batch of warning letters in early March 2026 targeting telehealth marketing of compounded GLP‑1 products. (fda.gov 1) (fda.gov 2)
